Amgen Drug Patent Portfolio
Amgen owns 1 orange book drug protected by 6 US patents Given below is the list of Amgen's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7829595 | Rapid dissolution formulation of a calcium receptor-active compound | 22 Sep, 2026 | Active |
| US9375405 | Rapid dissolution formulation of a calcium receptor-active compound | 22 Sep, 2026 | Active |
| US6011068 | Calcium receptor-active molecules | 08 Mar, 2018 | Expired |
| US6031003 | Calcium receptor-active molecules | 14 Dec, 2016 | Expired |
| US6313146 | Calcium receptor-active molecules | 14 Dec, 2016 | Expired |
| US6211244 | Calcium receptor-active compounds | 23 Oct, 2015 | Expired |
Latest Legal Activities on Amgen's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Amgen.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 21 Nov, 2023 | US9375405 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 21 Apr, 2022 | US7829595 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 13 Dec, 2019 | US9375405 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 27 Apr, 2018 | US7829595 |
| Post Issue Communication - Certificate of Correction | 13 Feb, 2018 | US9375405 |
|
Recordation of Patent Grant Mailed
Critical
| 28 Jun, 2016 | US9375405 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 28 Jun, 2016 | US9375405 |
|
Issue Notification Mailed
Critical
| 08 Jun, 2016 | US9375405 |
|
Application Is Considered Ready for Issue
Critical
| 25 May, 2016 | US9375405 |
| Dispatch to FDC | 25 May, 2016 | US9375405 |
|
Issue Fee Payment Received
Critical
| 24 May, 2016 | US9375405 |
|
Issue Fee Payment Verified
Critical
| 24 May, 2016 | US9375405 |
| Printer Rush- No mailing | 20 May, 2016 | US9375405 |
|
Information Disclosure Statement considered
Critical
| 19 May, 2016 | US9375405 |
|
Pubs Case Remand to TC
Critical
| 16 May, 2016 | US9375405 |
Amgen's Drug Patent Litigations
Amgen's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Oct 26, 2015, against patent number US7829595. The petitioner , challenged the validity of this patent, with None as the respondent. Click below to track the latest information on how companies are challenging Amgen's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US7829595 | October, 2015 |
Terminated-Denied
(13 Apr, 2016)
| ||
Amgen's Family Patents
Amgen Drug List
Given below is the complete list of Amgen's drugs and the patents protecting them.
1. Sensipar
Sensipar is protected by 6 patents, out of which 4 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7829595 | Rapid dissolution formulation of a calcium receptor-active compound |
22 Sep, 2026
(1 year, 7 months from now)
| Active |
| US9375405 | Rapid dissolution formulation of a calcium receptor-active compound |
22 Sep, 2026
(1 year, 7 months from now)
| Active |
| US6011068 | Calcium receptor-active molecules |
08 Mar, 2018
(6 years ago)
| Expired |
| US6031003 | Calcium receptor-active molecules |
14 Dec, 2016
(8 years ago)
| Expired |
| US6313146 | Calcium receptor-active molecules |
14 Dec, 2016
(8 years ago)
| Expired |
| US6211244 | Calcium receptor-active compounds |
23 Oct, 2015
(9 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Sensipar's drug page